Skip to content
iOnctura-new funding

iOnctura partners with the Dutch Cancer Society

Share this article

iOnctura announced that they have been awarded funding from the KWF Kankerbestrijding / Dutch Cancer Society to further the development of IOA-289 for fibrotic tumours.



This project focuses on a new drug for cancers with high levels of connective tissue formation, such as pancreatic cancer. The aim is to inhibit ‘bad’ connective tissue cells (which help the tumour) and preserve ‘good’ connective tissue cells (which oppose the tumour).

About iOnctura

iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways such as cellular proliferation; escape from immune detection; and drug resistance.

iOnctura’s pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone.


Source: press release